Skip to main content

Table 2 Mean VA and change in mean VA from baseline at 4, 12, 18 and 24 months

From: Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia

 

Group A

Group B

Number of patients

105

33

Number of eyes

115

33

 

Baseline

VA (mean ± SD)

57.9 ± 14.9

62.4 ± 12.4

p-value

0.0850

 

4 months

VA (mean ± SD)

63.6 ± 14.5

66.8 ± 12.4

Change in mean VA (95% CI)

5.5

5.4

95% CI

[3.7; 7.2]

[2.0; 8.7]

p-value

< 0.0001

0.0017

Difference in mean VA changes

0.1

95% CI

[−3.7; 3.9]

p-value

0.9619

 

12 months

VA (mean ± SD)

64.6 ± 15.8

68.5 ± 14.4

Change in mean VA (95% CI)

6.5

6.9

95% CI

[4.4; 8.6]

[3.0; 10.9]

p-value

< 0.0001

0.0008

Difference in mean VA changes

−0.5

95% CI

[−5.0; 4.0]

p-value

0.8378

 

18 months

VA (mean ± SD)

64.0 ± 15.0

65.8 ± 15.5

Change in mean VA (95% CI)

6.0

4.3

95% CI

[3.7; 8.3]

[0.1; 8.6]

p-value

< 0.0001

0.0467

Difference in mean VA changes

1.7

95% CI

[−3.1; 6.5]

p-value

0.4952

 

24 months

VA (mean ± SD)

64.8 ± 15.6

63.2 ± 17.3

Change in mean VA (95% CI)

7.0

1.2

95% CI

[4.7; 9.3]

[−3.1; 5.6]

p-value

< 0.0001

0.5733

Difference in mean VA changes

5.7

95% CI

[0.8; 10.6]

p-value

0.0224

  1. Group A: eyes receiving the TE regimen for 2 years; Group B: eyes receiving the TE regimen in Year 1 and the PRN regimen in Year 2. VA values refer to least-squares means. CI: confidence interval; PRN: pro re nata; SD: standard deviation; TE: treat-and-extend; VA: visual acuity